| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/11/2000 | CA1340957C Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics |
| 04/11/2000 | CA1340955C Stilbene derivatives |
| 04/11/2000 | CA1340951C Production and use of purpurins, chlorins and purpurin-and chlorin-containing compositions |
| 04/08/2000 | CA2285120A1 Heterocycles |
| 04/06/2000 | WO2000019206A1 Ykl-40 as a marker and prognostic indicator for cancers |
| 04/06/2000 | WO2000019200A1 Identifying agents that alter mitochondrial permeability transition pores |
| 04/06/2000 | WO2000018959A1 Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof |
| 04/06/2000 | WO2000018954A2 Use of pex in the treatment of metabolic bone diseases |
| 04/06/2000 | WO2000018947A1 Fermentation of clavulanic acid at a controlled level of ammonia |
| 04/06/2000 | WO2000018944A1 Triacylglycerols of enriched cla content |
| 04/06/2000 | WO2000018919A1 Human kinesin-like motor protein |
| 04/06/2000 | WO2000018918A2 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity |
| 04/06/2000 | WO2000018910A1 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof |
| 04/06/2000 | WO2000018885A1 Methods of controlling proliferation and differentiation of stem and progenitor cells |
| 04/06/2000 | WO2000018821A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties |
| 04/06/2000 | WO2000018797A1 Map |
| 04/06/2000 | WO2000018781A1 Antisense modulation of survivin expression |
| 04/06/2000 | WO2000018775A1 Antiviral purine derivatives |
| 04/06/2000 | WO2000018767A2 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| 04/06/2000 | WO2000018764A1 Benzimidazolinyl piperidines as cgrp ligands |
| 04/06/2000 | WO2000018761A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| 04/06/2000 | WO2000018760A1 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders |
| 04/06/2000 | WO2000018759A1 Phenylalanine derivatives as alpha 4 integrin inhibitors |
| 04/06/2000 | WO2000018758A1 Pyrimidone derivatives |
| 04/06/2000 | WO2000018753A1 2-phenylpyran-4-one derivatives |
| 04/06/2000 | WO2000018749A1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 04/06/2000 | WO2000018747A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
| 04/06/2000 | WO2000018744A1 Oxazole compounds as prostaglandin e2 agonists or antagonists |
| 04/06/2000 | WO2000018740A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| 04/06/2000 | WO2000018738A1 Benzamide derivatives and their use as cytokine inhibitors |
| 04/06/2000 | WO2000018735A1 2-substituted heterocyclic sulfonamides |
| 04/06/2000 | WO2000018734A1 Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes |
| 04/06/2000 | WO2000018733A1 Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals |
| 04/06/2000 | WO2000018725A1 2-substituted ketoamides |
| 04/06/2000 | WO2000018724A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY |
| 04/06/2000 | WO2000018723A1 Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| 04/06/2000 | WO2000018721A1 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| 04/06/2000 | WO2000018438A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof |
| 04/06/2000 | WO2000018432A1 Carbohydrate vaccines for viral diseases |
| 04/06/2000 | WO2000018424A1 Use of substances with oxytocin activity in order to create cell regeneration |
| 04/06/2000 | WO2000018419A2 Methods for administration of antibiotics |
| 04/06/2000 | WO2000018417A2 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine |
| 04/06/2000 | WO2000018411A1 VERY HIGH MOLECULAR WEIGHT β-GLUCANS |
| 04/06/2000 | WO2000018409A1 Use of certain drugs for treating nerve root injury |
| 04/06/2000 | WO2000018408A1 2-methyl-thieno-benzodiazepine formulation |
| 04/06/2000 | WO2000018407A1 Methods for preventing/treating damage to sensory hair cells and cochlear neurons |
| 04/06/2000 | WO2000018406A1 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
| 04/06/2000 | WO2000018405A1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 04/06/2000 | WO2000018404A1 Antibiotic compositions for treatment of the eye, ear and nose |
| 04/06/2000 | WO2000018402A1 Method for treating androgen-related conditions |
| 04/06/2000 | WO2000018401A1 Antimycotic drug composition |
| 04/06/2000 | WO2000018400A1 Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration |
| 04/06/2000 | WO2000018399A1 Preventive and/or therapeutic agents for sinusitis______________ |
| 04/06/2000 | WO2000018398A1 Pharmaceutically active compounds and methods of use thereof |
| 04/06/2000 | WO2000018397A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
| 04/06/2000 | WO2000018395A1 Method for preventing or delaying catheter-based revascularization |
| 04/06/2000 | WO2000018394A1 Adrenoleukodystrophy treatments and drug screening |
| 04/06/2000 | WO2000018393A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| 04/06/2000 | WO2000018392A1 Fructosamine oxidase: antagonists and inhibitors |
| 04/06/2000 | WO2000018391A1 Drugs for improving vesical excretory strength |
| 04/06/2000 | WO2000018389A2 USE OF A β2 ADRENERGIC RECEPTOR AGONIST IN THE TREATMENT OF CARDIOVASCULAR DISEASE |
| 04/06/2000 | WO2000018388A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 04/06/2000 | WO2000018387A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 04/06/2000 | WO2000018386A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 04/06/2000 | WO2000018385A2 Use of acylcarnitines as antitumour agents |
| 04/06/2000 | WO2000018384A2 Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir |
| 04/06/2000 | WO2000018383A2 Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester |
| 04/06/2000 | WO2000018381A1 Use of epinastine as antitussivum |
| 04/06/2000 | WO2000018379A2 Pharmaceutical preparation for use in a method to abate the use of tobacco by humans |
| 04/06/2000 | WO2000018375A1 Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as a coating agent, a binding agent and/or as a film-forming auxiliary agent in pharmaceutical forms of administration |
| 04/06/2000 | WO2000018374A1 Controlled release nanoparticulate compositions |
| 04/06/2000 | WO2000018373A1 Core tablet for controlled release of gliclazide after oral administration |
| 04/06/2000 | WO2000018369A1 Iontophoretic devices comprising piperidin derivatives |
| 04/06/2000 | WO2000018366A1 Oral composition with an improved teeth whitening effect |
| 04/06/2000 | WO2000018365A2 Fast dissolving orally consumable films |
| 04/06/2000 | WO2000018361A2 Method of treating hair loss using sulfonamides |
| 04/06/2000 | WO2000018358A2 Method of treating hair loss using ketoamides |
| 04/06/2000 | WO2000018353A2 A novel inhibitor of cataract formation |
| 04/06/2000 | WO2000018352A2 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 04/06/2000 | WO2000018351A2 Aglyco products and methods of use |
| 04/06/2000 | WO2000018338A1 Methods and apparatus for improved administration of fentanyl and sufentanil |
| 04/06/2000 | WO2000018316A2 Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| 04/06/2000 | WO2000018254A2 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability |
| 04/06/2000 | WO2000018234A1 Thiazolidenediones alone or in combination with other therapeutic agents for tumor therapy |
| 04/06/2000 | WO2000018233A1 Synthetic analogs of ecteinascidin-743 |
| 04/06/2000 | WO2000018232A1 Method of treatment of cardiovascular injuries |
| 04/06/2000 | WO2000018231A1 Methods for treating or preventing viral infections and associated diseases |
| 04/06/2000 | WO2000018230A1 Combination of bisphosphonate and tetracycline |
| 04/06/2000 | WO2000018212A2 Platelet-derived growth factor c, dna coding therefor, and uses thereof |
| 04/06/2000 | WO2000006588B1 STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| 04/06/2000 | WO2000004187A9 Methods and kits for diagnosing and determination of the predisposition of diseases |
| 04/06/2000 | WO2000001704A3 Benzimidazoles, production thereof and use thereof as medicaments |
| 04/06/2000 | WO2000001671A3 Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
| 04/06/2000 | WO1999066936A9 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
| 04/06/2000 | WO1999066914A3 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin |
| 04/06/2000 | WO1999065476A3 COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO) |
| 04/06/2000 | WO1999065475A3 Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| 04/06/2000 | WO1999065474A3 Compositions for treating cartilage disease comprising certain sulfur-containing heterocyclic compounds |
| 04/06/2000 | WO1999064424A8 Therapeutic agents |
| 04/06/2000 | WO1999064421A8 Acetylcholine enhancers |